accepted for restricted use, within its licensed indications,
for treating patients who are unable to swallow capsules.lMEDICINAL FORMS
There can be variation in the licensing of different medicines
containing the same drug. Forms available from special-order
manufacturers include: oral suspension, oral solution
Oral solution
CAUTIONARY AND ADVISORY LABELS 3
▶Strattera(Eli Lilly and Company Ltd)
Atomoxetine (as Atomoxetine hydrochloride) 4 mg per
1mlStrattera 4 mg/ 1 ml oral solution sugar-free| 300 mlP
£ 85. 00 DT = £ 85. 00
Capsule
CAUTIONARY AND ADVISORY LABELS 3
▶Strattera(Eli Lilly and Company Ltd)
Atomoxetine (as Atomoxetine hydrochloride) 10 mgStrattera
10 mg capsules| 7 capsuleP£ 13. 28 | 28 capsuleP£ 53. 09
DT = £ 53. 09
Atomoxetine (as Atomoxetine hydrochloride) 18 mgStrattera
18 mg capsules| 7 capsuleP£ 13. 28 | 28 capsuleP£ 53. 09
DT = £ 53. 09
Atomoxetine (as Atomoxetine hydrochloride) 25 mgStrattera
25 mg capsules| 7 capsuleP£ 13. 28 | 28 capsuleP£ 53. 09
DT = £ 53. 09
Atomoxetine (as Atomoxetine hydrochloride) 40 mgStrattera
40 mg capsules| 7 capsuleP£ 13. 28 | 28 capsuleP£ 53. 09
DT = £ 53. 09
Atomoxetine (as Atomoxetine hydrochloride) 60 mgStrattera
60 mg capsules| 28 capsuleP£ 53. 09 DT = £ 53. 09
Atomoxetine (as Atomoxetine hydrochloride) 80 mgStrattera
80 mg capsules| 28 capsuleP£ 70. 79 DT = £ 70. 79
Atomoxetine (as Atomoxetine hydrochloride) 100 mgStrattera
100 mg capsules| 28 capsuleP£ 70. 79 DT = £ 70. 79
Methylphenidate hydrochloride 03-Oct-2017
lINDICATIONS AND DOSE
Attention deficit hyperactivity disorder (initiated under
specialist supervision)
▶BY MOUTH USING IMMEDIATE-RELEASE MEDICINES
▶Child 4–5 years:Initially 2. 5 mg twice daily, increased in
steps of 2. 5 mg daily if required, at weekly intervals,
increased if necessary up to 1. 4 mg/kg daily in
2 – 3 divided doses, discontinue if no response after
1 month, if effect wears off in evening (with rebound
hyperactivity) a dose at bedtime may be appropriate
(establish need with trial bedtime dose). Treatment
may be started using a modified-release preparation
▶Child 6–17 years:Initially 5 mg 1 – 2 times a day,
increased in steps of 5 – 10 mg daily if required, at
weekly intervals, increased if necessary up to 60 mg
daily in 2 – 3 divided doses, increased if necessary up to
2. 1 mg/kg daily in 2 – 3 divided doses, the licensed
maximum dose is 60 mg daily in 2 – 3 doses, higher dose
(up to a maximum of 90 mg daily) under the direction
of a specialist, discontinue if no response after
1 month, if effect wears off in evening (with rebound
hyperactivity) a dose at bedtime may be appropriate
(establish need with trial bedtime dose). Treatment
may be started using a modified-release preparation
DOSE EQUIVALENCE AND CONVERSION
▶When switching fromimmediate-releasepreparations
tomodified-releasepreparations—consult product
literature.
CONCERTA®XL
Attention deficit hyperactivity disorder
▶BY MOUTH
▶Child 6–17 years:Initially 18 mg once daily, dose to be
taken in the morning, increased in steps of 18 mg every
week, adjusted according to response; increased if
necessary up to 2. 1 mg/kg daily, licensed max. dose is
54 mg once daily, to be increased to higher dose onlyunder direction of specialist; discontinue if no
response after 1 month; maximum 108 mg per day
DOSE EQUIVALENCE AND CONVERSION
▶Total daily dose of 15 mg of standard-release
formulation is considered equivalent toConcerta®XL
18 mg once daily.
DELMOSART®PROLONGED-RELEASE TABLET
Attention deficit hyperactivity disorder (under expert
supervision)
▶BY MOUTH
▶Child 6–17 years:Initially 18 mg once daily, dose to be
taken in the morning, then increased in steps of 18 mg
every week if required, discontinue if no response
after 1 month; maximum 54 mg per day
DOSE EQUIVALENCE AND CONVERSION
▶Total daily dose of 15 mg of standard-release
formulation is considered equivalent toDelmosart®
18 mg once daily.
EQUASYM®XL
Attention deficit hyperactivity disorder
▶BY MOUTH
▶Child 6–17 years:Initially 10 mg once daily, dose to be
taken in the morning before breakfast; increased
gradually at weekly intervals if necessary; increased if
necessary up to 2. 1 mg/kg daily, licensed max. dose is
60 mg daily, to be increased to higher dose only under
direction of specialist; discontinue if no response after
1 month; maximum 90 mg per day
MEDIKINET®XL
Attention deficit hyperactivity disorder
▶BY MOUTH
▶Child 6–17 years:Initially 10 mg once daily, dose to be
taken in the morning with breakfast; adjusted at
weekly intervals according to response; increased if
necessary up to 2. 1 mg/kg daily, licensed max. dose is
60 mg daily, to be increased to higher dose only under
direction of specialist; discontinue if no response after
1 month; maximum 90 mg per day
XAGGITIN®XL
Attention deficit hyperactivity disorder (under expert
supervision)
▶BY MOUTH
▶Child 6–17 years:Initially 18 mg once daily, dose to be
taken in the morning, increased in steps of 18 mg every
week, adjusted according to response, discontinue if no
response after 1 month; maximum 54 mg per day
DOSE EQUIVALENCE AND CONVERSION
▶Total daily dose of 15 mg of standard-release
formulation is considered equivalent toXaggitin®XL
18 mg once daily.lUNLICENSED USEDoses over 60 mg daily not licensed;
doses ofConcerta XLover 54 mg daily not licensed.
Not licensed for use in children under 6 years.
lCONTRA-INDICATIONSAnorexia nervosa.arrhythmias.
cardiomyopathy.cardiovascular disease.cerebrovascular
disorders.heart failure.hyperthyroidism.
phaeochromocytoma.psychosis.severe depression.
severe hypertension.structural cardiac abnormalities.
suicidal ideation.uncontrolled bipolar disorder.vasculitis
lCAUTIONSAgitation.alcohol dependence.anxiety.drug
dependence.epilepsy (discontinue if increased seizure
frequency).family history of Tourette syndrome.
susceptibility to angle-closure glaucoma.tics
CONCERTA®XLDysphagia (dose form not appropriate).
restricted gastro-intestinal lumen (dose form not
appropriate)BNFC 2018 – 2019 Attention deficit hyperactivity disorder 227
Nervous system4